Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043706
Status:
COMPLETED
Last Update Posted:
2015-03-05
First Post:
2002-08-12
Brief Title:
Safety Tolerability and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis
Sponsor:
Organization:
Sanofi
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: